EC Number   |
Disease |
PubMed ID |
Title of Publication |
Category |
Confidence Level |
|---|
   6.2.1.59 | Infections |
20017806 |
T-cell responses and in vivo cytotoxicity in the target organ and the regional lymphoid tissue during airborne infection with the virulent Mycobacterium tuberculosis MT103 and its lipid mutant fadD26. |
causal interaction
ongoing research
therapeutic application
unassigned |
1
3
1
0 |
| 6.2.1.59 | long-chain fatty acid adenylase/transferase fadd26 deficiency |
17194612 |
Effect of phthiocerol dimycocerosate deficiency on the transcriptional response of human macrophages to Mycobacterium tuberculosis. |
causal interaction
unassigned |
3
0 |
| 6.2.1.59 | Pneumonia |
15958066 |
Immunogenicity and protective efficacy of the Mycobacterium tuberculosis fadD26 mutant. |
ongoing research
therapeutic application
unassigned |
1
2
0 |
| 6.2.1.59 | Tuberculosis |
11279114 |
Analysis of the phthiocerol dimycocerosate locus of Mycobacterium tuberculosis. Evidence that this lipid is involved in the cell wall permeability barrier. |
unassigned |
0 |
| 6.2.1.59 | Tuberculosis |
15958066 |
Immunogenicity and protective efficacy of the Mycobacterium tuberculosis fadD26 mutant. |
ongoing research
therapeutic application
unassigned |
1
2
0 |
| 6.2.1.59 | Tuberculosis |
17194612 |
Effect of phthiocerol dimycocerosate deficiency on the transcriptional response of human macrophages to Mycobacterium tuberculosis. |
causal interaction
unassigned |
3
0 |
| 6.2.1.59 | Tuberculosis |
20017806 |
T-cell responses and in vivo cytotoxicity in the target organ and the regional lymphoid tissue during airborne infection with the virulent Mycobacterium tuberculosis MT103 and its lipid mutant fadD26. |
causal interaction
ongoing research
therapeutic application
unassigned |
1
3
1
0 |
| 6.2.1.59 | Tuberculosis |
20553505 |
Delineation of the roles of FadD22, FadD26 and FadD29 in the biosynthesis of phthiocerol dimycocerosates and related compounds in Mycobacterium tuberculosis. |
ongoing research
unassigned |
1
0 |
| 6.2.1.59 | Tuberculosis |
23965219 |
Construction, characterization and preclinical evaluation of MTBVAC, the first live-attenuated M. tuberculosis-based vaccine to enter clinical trials. |
causal interaction
diagnostic usage
unassigned |
1
2
0 |
| 6.2.1.59 | Tuberculosis |
25066740 |
Hyper-attenuated MTBVAC erp mutant protects against tuberculosis in mice. |
ongoing research
therapeutic application
unassigned |
3
1
0 |
